VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRXGet Rating) in a research report released on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Maxim Group reduced their price objective on VolitionRx from $8.00 to $5.00 and set a buy rating for the company in a research note on Tuesday, August 23rd.

VolitionRx Price Performance

Shares of VNRX opened at $1.69 on Wednesday. The company has a 50-day moving average price of $2.03. VolitionRx has a one year low of $1.54 and a one year high of $4.14. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.07 and a current ratio of 1.07. The firm has a market cap of $96.83 million, a P/E ratio of -3.02 and a beta of 1.62.

VolitionRx Company Profile

(Get Rating)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.

Featured Articles

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.